Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Benjamin Haefliger

Showing results (1-10 of 8) with videos related to

Pageof 1
Sort By:
Cell Reports|August 23, 2016
Synthetic Biology Platform for Sensing and Integrating Endogenous Transcriptional Inputs in Mammalian CellsBartolomeo Angelici, Erik Mailand, Benjamin Haefliger, et al.
Nature Communications|February 17, 2016
Precision multidimensional assay for high-throughput microRNA drug discoveryBenjamin Haefliger, Laura Prochazka, Bartolomeo Angelici, et al.
Nature Communications|October 15, 2014
Highly modular bow-tie gene circuits with programmable dynamic behaviourLaura Prochazka, Bartolomeo Angelici, Benjamin Haefliger, et al.
Molecular Systems Biology|December 30, 2016
Model-guided combinatorial optimization of complex synthetic gene networksJoerg Schreiber, Meret Arter, Nicolas Lapique, et al.
Future Oncology (London, England)|September 14, 2023
Real-world treatment patterns, healthcare resource use and disease burden in patients with multiple myeloma in EuropeJoaquín Martínez-Lopez, Abigail Bailey, Annabel Lambert, et al.
Cancers|December 10, 2021
Adjusted Comparison of Outcomes between Patients from CARTITUDE-1 versus Multiple Myeloma Patients with Prior Exposure to PI, Imid and Anti-CD-38 from a German RegistryMaximilian Merz, Hartmut Goldschmidt, Parameswaran Hari, et al.
Hemasphere|December 8, 2022
Ciltacabtagene Autoleucel for Patients With Triple-class Exposed Multiple Myeloma: Adjusted Comparison of CARTITUDE-1 Patient Outcomes Versus Real-world Clinical PracticeMichel Delforge, Marie-Christiane Vekemans, Julien Depaus, et al.
Haematologica|December 22, 2022
Adjusted comparison of outcomes between patients from CARTITUDE-1 <i>versus</i> multiple myeloma patients with prior exposure to proteasome inhibitors, immunomodulatory drugs and anti-CD38 antibody from the prospective, multinational LocoMMotion study of real-world clinical practiceMaria-Victoria Mateos, Katja Weisel, Thomas Martin, et al.
Pageof 1

Showing results (1-10 of 8) with videos related to

Sort By:
Pageof 1
Cell Reports|August 23, 2016
Synthetic Biology Platform for Sensing and Integrating Endogenous Transcriptional Inputs in Mammalian CellsBartolomeo Angelici, Erik Mailand, Benjamin Haefliger, et al.
Nature Communications|February 17, 2016
Precision multidimensional assay for high-throughput microRNA drug discoveryBenjamin Haefliger, Laura Prochazka, Bartolomeo Angelici, et al.
Nature Communications|October 15, 2014
Highly modular bow-tie gene circuits with programmable dynamic behaviourLaura Prochazka, Bartolomeo Angelici, Benjamin Haefliger, et al.
Molecular Systems Biology|December 30, 2016
Model-guided combinatorial optimization of complex synthetic gene networksJoerg Schreiber, Meret Arter, Nicolas Lapique, et al.
Future Oncology (London, England)|September 14, 2023
Real-world treatment patterns, healthcare resource use and disease burden in patients with multiple myeloma in EuropeJoaquín Martínez-Lopez, Abigail Bailey, Annabel Lambert, et al.
Cancers|December 10, 2021
Adjusted Comparison of Outcomes between Patients from CARTITUDE-1 versus Multiple Myeloma Patients with Prior Exposure to PI, Imid and Anti-CD-38 from a German RegistryMaximilian Merz, Hartmut Goldschmidt, Parameswaran Hari, et al.
Hemasphere|December 8, 2022
Ciltacabtagene Autoleucel for Patients With Triple-class Exposed Multiple Myeloma: Adjusted Comparison of CARTITUDE-1 Patient Outcomes Versus Real-world Clinical PracticeMichel Delforge, Marie-Christiane Vekemans, Julien Depaus, et al.
Haematologica|December 22, 2022
Adjusted comparison of outcomes between patients from CARTITUDE-1 <i>versus</i> multiple myeloma patients with prior exposure to proteasome inhibitors, immunomodulatory drugs and anti-CD38 antibody from the prospective, multinational LocoMMotion study of real-world clinical practiceMaria-Victoria Mateos, Katja Weisel, Thomas Martin, et al.
Pageof 1